• Keine Ergebnisse gefunden

Supplementary Figure 3. Individual angiotensin levels before and after placebo or eplerenone treatment in CKD patients with T2DM.

N/A
N/A
Info
Herunterladen
Protected

Academic year: 2022

Aktie "Supplementary Figure 3. Individual angiotensin levels before and after placebo or eplerenone treatment in CKD patients with T2DM."

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Jetzt herunterladen ( 1 Seite )

Volltext

(1)

Supplementary Figure 3. Individual angiotensin levels before and after placebo or eplerenone treatment in CKD patients with T2DM. For better visualization data are plotted logarithmically on the y-axis.

Placebo pre

Placebo post

1 1 0 1 0 0 1 0 0 0 1 0 0 0 0

Ang I [pmol/L]

Eplerenone pre

Eplerenone post

1 1 0 1 0 0 1 0 0 0 1 0 0 0 0

Ang I [pmol/L]

Placebo pre

Placebo post

1 1 0 1 0 0 1 0 0 0

Ang II [pmol/L]

Eplerenone pre

Eplerenone post

1 1 0 1 0 0 1 0 0 0

Ang II [pmol/L]

Placebo pre

Placebo post

1 1 0 1 0 0 1 0 0 0

Ang-(1-7) [pmol/L]

Eplerenone pre

Eplerenone post

1 1 0 1 0 0 1 0 0 0

Ang-(1-7) [pmol/L]

Referenzen

Jetzt herunterladen ( PDF - 1 Seite - 189.42 KB )

ÄHNLICHE DOKUMENTE

Defoliation of the vines before or after berry set: Physiologicalconsequences and qualitative factors

A defoliation that is effectuated very early (stage of separated flower buds) and intensively (100 % of the bunch zone at the level of six leaves including the lateral shoots)

Supplementary Figure 4. Individual Aldosterone, PRA-S and ACE-S levels before and after placebo or eplerenone treatment in CKD patients with T2DM.

Individual Aldosterone, PRA-S and ACE-S levels before and after placebo or eplerenone treatment in CKD patients with

Supplemental Tables Supplemental Table 1. Comparison of texture features before and after treatment in group T (treatment with tocilizumab) and in group non-T (treatment without tocilizumab).

GLZLM: Grey-Level Zone Length Matrix.... HU:

Patients with Oral Tumors; Part 2: Quality of Life after Treatment with Resection Prostheses

The EORTC QLQ-C30 (Version 3.0) is the core questionnaire, and contains 30 questions on general health and well-being (Q1–Q30), both of which are especially compromised in tumor

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data

Therefore, these studies were evaluated for both the on study mortality and overall survival analysis restricted to the active treatment phase during which con- trol patients did

Treatment outcomes and mortality of 94 patients with acromegaly

In seven patients stereotactic radiotherapy was per- formed [27] and control of disease was obtained after one year in 2 patients suggesting a more rapid achieve- ment of safe GH

Oral health of patients with severe haematological malignancies and disorders before and after haematopoietic stem cell transplantation

Several studies have found that the oral health status of patients with haematological malignancies prior to cancer treatments may correlate with comorbidities,

Personalising treatment in patients with carotid disease

Several randomised trials are currently investigating this question, including the Second European Carotid Surgery Trial (ECST-2), the Stent Protected Angioplasty